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Background: Dermatofibrosarcoma protuberans (DFSP) is a cutaneous soft tissue sarcoma characterized by an
indolent but aggressive local growth. Unplanned excisions with positive margins are common, and the prognostic
impact of radical re-excisions is still unclear. The aim of the present study was to identify prognostic indicators of
recurrence-free survival (RFS) in patients with DFSP through a long-term follow-up. We tried particularly to
determine the prognostic impact of surgical margins and re-excisions in patients after earlier inadequate surgery.
Methods: Seventy-five patients with DFSP were treated surgically at our institution between 1999 and 2015.
Analyses were restricted to 68 participants with available information on surgical margins. The median follow-up
was 5.4 years.
Results: Fifty-four patients (79.4%) had low-grade DFSP and 14 patients (20.6%) intermediate-grade FS-DFSP. The
5-year RFS rates were estimated to be 93.5% (95% CI 81.2–97.9) for low-grade DFSP and 39.7% (95% CI 13.0–65.8) for
FS-DFSP (P < 0.0001). Re-excisions were performed in 55 patients (80.9%) following R1 or marginal R0 resections.
Negative margins could be attained in a total of 65 patients (95.6%). Negative margin widths >1 cm led to the best
local outcome within the R0 subgroup. Significant adverse prognostic features in the multivariate analysis included
histologic grade and close margins.
Conclusions: The data from this study underscore the long-term benefit of negative margins. In our analysis, re-excisions
were an effective method to achieve a high rate of local control in patients who presented after R1 or marginal
R0 resection. To ensure the best outcome, re-excisions should aim at negative margin widths of more than 1 cm
in the histologic specimen.
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Dermatofibrosarcoma protuberans (DFSP) is a rare, cuta-
neous soft tissue sarcoma of fibroblastic origin. It accounts
for approximately 1% of all soft tissue sarcomas with an
estimated incidence of three to five cases per million per-
sons [1, 2]. DFSP can occur throughout the body, but it is
localized predominantly at the trunk and the proximal ex-
tremities [3, 4]. Its clinical behaviour is characterized by
an indolent, but local, aggressive growth with destructive
infiltration of the surrounding tissues. Patients rarely die
from DFSP due to its low metastatic potential: less than
5% of all patients develop distant metastases [4–8]. Histo-
logically, approximately 90% of all DFSPs are low-grade
lesions while 10% contain fibrosarcomatous components
(FS-DFSP). The FS-DFSP subtype is, therefore, considered
as an intermediate-grade sarcoma displaying a more ag-
gressive growth pattern with a higher rate of local recur-
rences and metastases [9–12].
At a molecular level, more than 90% of all DFSP arise
from the translocation of chromosomes 17 and 22, result-
ing in a fusion between the collagen type Iα1 gene
(COL1A1) and the platelet-derived growth factor β-chain
gene (PDGFB) [13, 14]. This rearrangement causes a con-
tinuous activation of platelet-derived growth factor recep-
tor β (PDGFRβ) protein tyrosine kinase, which promotes
DFSP cell growth. The correlating signalling pathway can
be targeted by tyrosine kinase inhibitors, such as imatinib
and sunitinib, which have been revealed to be promising
candidates in the treatment of metastatic or locally ad-
vanced DFSP that were not suitable for further curative
resection [15–17]. Currently, imatinib is approved in Eur-
ope for the treatment of inoperable tumours and meta-
static DFSP.
The standard curative treatment for DFSP to date still
remains surgical resection with wide, clear margins. Due to
its distinctive storiform growth pattern with pseudopod-
like extensions, incomplete excisions are relatively com-
mon, especially in “whoops” procedures, where banal
lesions were expected preoperatively. The data available
on local recurrence rates after surgical excision are rela-
tively heterogeneous, ranging from 0 to 57% [6, 8, 18]. Not-
ably, the local recurrence rates for Mohs micrographic
surgery (MMS) reported, ranging from 0 to 1.1%, are sig-
nificantly superior to those for wide local excisions (WLE),
at 0 to 27% [2, 3, 5, 7, 8, 19–27]. The European
Association of Dermato-Oncology (EADO) and the
European Organization of Research and Treatment of
Cancer (EORTC) recommend MMS to reduce the local
recurrence rates and to minimize the amount of excised
tissue, particularly at the head and neck area, in a position
paper published currently. However, WLE with a lateral
safety margin of 3 cm was advised in treatment centres
where only standard histopathological procedures are
available [28]. Several treatment centres suggested safetymargins ranging from 2 to even 5 cm, but they did not dif-
ferentiate clearly between the safety margin planned pre-
operatively and the margin width histologically assessed
postoperatively [2, 7, 8, 10, 24, 25, 27, 29]. Nevertheless, it
seems reasonable that wider safety margins might be asso-
ciated with more favourable outcomes, but a more precise
cutoff point has yet to be assessed. Although reconstructive
plastic surgery can frequently reduce functional impair-
ment and cover soft tissue defects, the surgical approach
with such wide safety margins is associated with consider-
able morbidity and should, therefore, be weighed up
carefully.
In the current study, we reviewed our own institu-
tional experience and assessed the prognostic signifi-
cance of negative margin widths in patients with low-
grade DFSP and FS-DFSP. In particular, we tried to de-




Seventy-five patients with DFSP of the trunk, the ex-
tremities, the head and the neck were treated surgically
at our institution between January 1999 and September
2015. A total of 20 of the 75 patients presented with pri-
mary disease at our institution. Fifty-five patients were
referred to our tertiary centre subsequently after incom-
plete resections. From this group, we excluded five pa-
tients because essential data regarding the initial surgical
procedure, such as tumour size or margin status, were
not available. Furthermore, two patients were lost to
follow-up. Thus, we restricted the analyses to 68 partici-
pants with full information available on the outcome
and surgical margins at the initial procedure. They were
assessed and their clinicopathological characteristics
are summarized in Table 1. Patient follow-up was ob-
tained from our database, medical records and patient
correspondence.
Ethics approval and consent to participate
The retrospective analysis was approved by the Ethics
Committee of the Medical Faculty of the Ruhr-University
Bochum (Registration number 15-5441). Patients gave
written informed consent to participate.
Treatment
The goal of surgical treatment for all patients was the
complete resection of the primary or residual tumour
with wide, clear margins. This resection included the
scars from previous surgeries, biopsies and wound drain-
age. If necessary, immediate or delayed soft tissue cover-
age was performed with split thickness skin grafts, and
local or free flaps. No patients in this series were treated
with MMS.
Table 1 Results of univariate analyses to determine patient and tumour dependent factors predictive of recurrence-free survival
N Estimated 1-year RFS (95% CI) Estimated 2-year RFS (95% CI) Estimated 5-year RFS (95% CI) P (log-rank)*
Age (years)
<60 55 96.2 (85.6–99.0) 91.5 (78.7–96.7) 86.5 (72.3–93.8) 0.075
≥60 13 69.2 (37.3–87.2) 69.2 (37.3–87.2) 69.2 (37.3–87.2)
Sex
Female 35 81.8 (63.9–91.4) 78.4 (59.9–89.1) 78.4 (59.9–89.1) 0.237
Male 33 100 (−) 96.2 (75.7–99.4) 87.2 (65.2–95.7)
Site
Upper extremity 20 77.1 (49.5–90.9) 70.7 (42.8–86.8) 63.6 (35.7–82.0) 0.013
Lower extremity 17 93.8 (63.2–99.1) 93.8 (63.2–99.1) 93.8 (63.2–99.1) 0.237
Head/neck 8 85.7 (33.4–97.9) 85.7 (33.4–97.9) 71.4 (25.8–92.0) –
Trunk 23 100 (−) 94.1 (65.0–99.1) 94.1 (65.0–99.1) 0.086
Tumour size
<2 cm 36 94.3 (79.0–98.5) 90.8 (73.9–97.0) 90.8 (73.9–97.0) 0.123
≥2 cm 32 86.1 (67.1–94.6) 82.4 (62.7–92.3) 73.5 (51.8–86.5)
Histologic grade
G1 (low-grade DFSP) 54 95.9 (84.7–99.0) 93.5 (81.2–97.9) 93.5 (81.2–97.9)
G2 (FS-DFSP) 14 68.1 (35.4–86.8) 59.6 (28.2–80.9) 39.7 (13.0–65.8) <0.0001
RFS recurrence-free survival, CI confidence interval
*Log-rank test for equality of survivor functions
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discretion of the interdisciplinary tumour board of our
institution. Adjuvant radiation was recommended after
incomplete surgical resection.
Histopathological classification
All tumours were diagnosed and classified using the
guidelines of the French Federation of Cancer Centres
(FNCLCC) and those of the World Health Organization
(WHO). Surgical margins were assessed after fixation of
the pathologic specimen with formalin and dyeing the
surface with ink. All pathology slides were analysed or
reviewed for consensus diagnosis by experienced soft tis-
sue pathologists from our institution.
Statistical analysis
All patients were retrospectively analysed regarding pos-
sible prognostic factors influencing recurrence-free sur-
vival (RFS). The RFS was defined as the time period
from the date of surgery at our institution to the date of
first recurrence or censored at the date of last follow-up
assessment in recurrence-free patients. The RFS rates
were estimated according to the Kaplan-Meier method
with respective 95% confidence intervals (CIs) and were
compared using the log-rank test. Multivariate analyses
were performed using the Cox proportional hazards
model and the Wald test. Variables that were associated
with P < 0.05 in the univariate analysis were included
in the multivariate regression to assess independentprognostic factors. The data analysis was performed
using the statistical programme Stata (Version 11.2,
StataCorp, College Station, TX, USA).
Results
Patient characteristics and surgical margins
The median follow-up after primary diagnosis as of
February 2016 (cutoff date) was 5.4 years. The median
age at the time of primary diagnosis was 42.2 years
(range 2.9–75.6). There were 35 female and 33 male pa-
tients. Fifty-four patients (79.4%) had low-grade (G1)
DFSP and 14 (20.6%) had intermediate-grade (G2) FS-
DFSP. The tumours were located in the lower extrem-
ities in 17 patients (25%) in the upper extremities in 20
patients (29.4%), in the trunk in 23 patients (33.9%) and
in the head and neck area in eight patients (11.8%).
Sixty-two patients had epifascial tumours, while only six
patients had tumours with subfascial involvement. The
median tumour size was 1.9 cm (range 0.1–20.0 cm).
The primary resection at the initial surgical procedure
led to microscopically negative margins (R0) in only 13
patients (19.1%), whereas 54 patients (79.4%) were left
with microscopically positive margins (R1) and one (1.5%)
with macroscopically positive margins (R2). Three patients
with FS-DFSP received adjuvant radiotherapy after the
resection of the primary tumour. Nine more patients
underwent radiotherapy after initial local recurrence.
Fifty-three patients with incompletely resected tumours
and two patients after marginal R0 resection subsequently
Harati et al. World Journal of Surgical Oncology  (2017) 15:5 Page 4 of 9underwent re-excisions at our institution. Residual disease
was detected histologically in the pathologic specimen in
47 of these 55 patients (85.5%). At the re-excision, micro-
scopically negative margins were attained in 52 of the 55
patients mentioned (94.5%). Tumours infiltrated critical
anatomic structures or were too advanced and widespread
for complete resection that would have resulted in func-
tion loss and increased morbidity in the remaining three
patients with R1 margins. Hence, microscopically positive
margins were tolerated consensually in these patients.
Continuous follow-ups with contrast-enhanced MRIs de-
tected progressive disease in two of these patients. The
histologically assessed closest negative margin width could
be obtained from the database in 48 patients with R0
resected tumours at the very initial procedure or forth-
coming re-excisions. Plastic surgical soft tissue coverage
had to be performed in 32 patients (47.1%) involving local
flaps (28), free flaps (3) and split thickness skin grafting
(1). One patient was amputated at the proximal phalanx
of his ring finger after early local recurrence.
Tumour resection and soft tissue coverage were usu-
ally performed as a one-step procedure to minimize the
risk of wound contamination or infection. However, in
some cases where complicated flaps were required for
soft tissue reconstruction, the defects were covered tem-
porarily with vacuum dressings. Six (21.4%) of the local
flaps and one (33.2%) of the free flaps had been trans-
ferred in a second or even third procedure after histo-
logical examination.
A lateral clear margin of 2.0 cm of normal tissue was
intended wherever feasible. The median negative margin
width was 0.35 cm in patients presenting with primary
tumours at our institution. Patients that underwent in-
complete resections at the referring institutions or prac-
tices were resected with a gross margin width of 2.0 cm
around the scars. The median clear margin width was
0.8 cm in re-excised patients.
A total of ten patients had at least one local recurrence
during the follow-up period, whereas four patients had
two or more local recurrences (range 2–6). The tumour
and treatment characteristics of these ten patients are
displayed in Table 2. No patient developed distant me-
tastases or died because of disease, while three patients
died for reasons other than DFSP.
Univariate analysis of survival
The Kaplan-Meier estimated rate of RFS after 5 years
was 82.6% (95% CI 70.0–90.3) for the entire series. Age,
gender and tumour size were not found to be significant
predictors of RFS (Table 1). Tumours arising in the
upper extremities had a worse prognosis compared to le-
sions at other sites (5-year RFS 63.6% [35.7–82.0] vs.
90.1% [75.6–96.2]; P = 0.013) (Fig. 1a). Similar to find-
ings in other studies, patients with low-grade (G1) DFSPhad more favourable prognoses than patients with inter-
mediate (G2) FS-DFSP. The 5-year RFS rates were esti-
mated to be 93.5% (95% CI 81.2–97.9) for G1 DFSP and
39.7% (95% CI 13.0–65.8) for G2 FS-DFSP (P < 0.0001)
(Table 1, Fig. 1b).
It is noteworthy that patients who had already under-
gone a R0 resection at the initial procedure appeared to
have a worse prognosis compared to patients who had
been resected only incompletely and, therefore, had to
undergo further re-excision (5-year RFS 63.3% [28.6–84.6]
vs. 87.1% [73.3–94.0]), although this survival distribution
failed to reach statistical significance in the univariate ana-
lysis and a borderline P value was attained (P = 0.053)
(Table 3). However, patients who underwent re-excision
had a significantly improved RFS (5-year RFS 89.6%
[76.7–95.6] vs. 47.9% [15.5–74.7]; P = 0.002) (Fig. 2).
Margins above 1 cm in the univariate analysis of cate-
gorized clear margin widths led to a significantly better
outcome when compared with closer margins (Table 3).
Another interesting observation was made when analys-
ing the type of wound closure carried out after the first
treatment round. Here, the use of reconstructive plastic
surgical soft tissue coverage involving skin grafting and
local and free flaps was associated with a more
favourable outcome when compared to primary closure
(5-year RFS 96.2% [75.7–99.4] vs. 69.7% [49.6–83.1];
P = 0.006) (Table 3).
Multivariate analysis of survival
The most significant prognostic factor for RFS in the
Cox model was the histologic grade (Table 4). The haz-
ard ratio (HR) for local recurrence was 5.99 (95% CI
1.15–31.34; P = 0.034) for patients with G2 FS-DFPS.
Re-excision was another independent predictor of RFS:
Patients who underwent re-excision had a significantly
lower risk of local failure (HR 0.23; 95% CI 0.06–0.93;
P = 0.039). The site of the tumour and the use of re-
constructive soft tissue coverage were significant indica-
tors of RFS in the univariate analysis but failed to reach
statistical significance in the multivariate analysis.
In an additional multivariate analysis, we determined in-
dependent prognostic factors for RFS in the subgroup of
patients with R0 resections and data available on margin
widths (Table 5). In accordance with the multivariate ana-
lysis of the entire cohort, the histologic grade was found
to be an independent predictive factor. Moreover, a nega-
tive margin width >1.0 cm could also be determined as a
significant independent prognostic factor of RFS.
Regression analysis of non-categorized surgical margin
width
Clear margins were found to be a significant predictor of
RFS in the Cox regression analysis and were inversely
proportional to the risk of local recurrence: the wider
Table 2 Tumour and treatment characteristics of patients with local recurrence
Case no. Entity Number of
recurrences
Margin status after initial








1 DFSP 2 R0 No R0 0.3 24
2 FS-DFSP 1 R1 No R1 – 26
3 DFSP 1 R0 No R0 0.2 4
4 FS-DFSP 1 R0 No R0 0.2 14
5 FS-DFSP 1 R1 Yes R0 0.3 4
6 FS-DFSP 8 R1 Yes R0 1.0 9
7 FS-DFSP 6 R1 Yes R1 – 30
8 FS-DFSP 5 R1 Yes R0 0.8 8
9 FS-DFSP 1 R1 Yes R0 0.2 3
10 DFSP 1 R0 No R0 Not available 5
RFS recurrence-free survival, CI confidence interval
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failure. This distribution in the Wald test was statisti-
cally significant, and the HR for local recurrence was
0.22 (95% CI 0.06–0.80) for negative margins with
>1 cm healthy tissue at the closest distance (P = 0.021).Fig. 1 Estimated recurrence-free survival curves depending on
tumour site (a) and histologic grade (b)Discussion
The rarity of DFSP and the low number of recurrence
events pose epidemiological challenges and preclude even
large studies to assess the prognostic factors of RFS. Der-
matofibrosarcoma protuberans can lead to significant mor-
bidity due to its aggressive local growth and the high rates
of local recurrence despite surgical resection. In the present
study, 15.4% of all R0 resected patients developed a local re-
currence during the course of the disease. The two largest,
well-characterized studies from the Instituto Nazionale
Tumori (INT) and the Memorial Sloan-Kettering Cancer
Center (MSKCC) presented cohorts with local recurrence
rates of 4.3 and 22.1%, respectively [4, 5]. The distinct vari-
ation between those two studies reflects the differences in
tumour histology, as the INT series contained a lower
percentage (3.2%) of patients with the more aggressive FS-
DFSP subtype than the MSKCC series (17%). In the present
study, a relatively high proportion of patients (20.6%) had a
FS-DFSP, which was found to be one of the most significant
adverse predictors of RFS in our study. Hence, the
observation of high recurrence rates is probably due
to differences in patient selection and the correspond-
ing tumour pathology between the two institutions re-
ported and our institution.
Incomplete resections in the form of “whoops” proce-
dures are common in the previous history of DFSP pa-
tients. A total of 79.2% of all patients referred came to our
institution after incomplete resections. However, further
re-excision led to negative margins in nearly all cases, ex-
cept for three patients. It is notable that pathologic re-
sidual disease could be detected in 85.5% of the re-excised
patients. In our series, re-excision to achieve wide, clear
margins has been determined to be an effective method of
achieving a high rate of local control in patients who pre-
sented after R1 or marginal R0 resection. This finding








Margin status after initial resection
R0 13 83.1 (47.2–95.5) 63.3 (28.6–84.6) 63.3 (28.6–84.6)
R1/2 55 91.9 (79.8–96.9) 91.9 (79.8–96.9) 87.1 (73.3–94.0) 0.053
Re-excision
No 13 82.1 (44.4–95.3) 59.8 (24.1–83.1) 47.9 (15.5–74.7)
Yes 55 92.0 (80.1–96.9) 92.0 (80.1–96.9) 89.6 (76.7–95.6) 0.002
Margin status after first treatment round (initial resection + re-excision)
R0 65 89.9 (78.8–95.3) 86.0 (73.9–92.8) 84.0 (71.3–91.4)
R1 3 100 (−) 100 (−) (−) –
Wound closure during first treatment round
Primary closure 35 80.8 (62.1–90.9) 73.6 (53.8–85.9) 69.7 (49.6–83.1)
Non-primary closure (plastic surgical tissue transfer) 32 100 (−) 100 (−) 96.2 (75.7–99.4) 0.006
Adjuvant radiotherapy
No 65 89.9 (78.8–95.3) 86.0 (73.9–92.8) 82.0 (69.0–89.9)
Yes 3 100 (−) 100 (−) 100 (−) –
Distance of closest negative margin (R0 group) in cm
≤0.2 11 81.8 (44.7–95.1) 71.6 (35.0–89.9) 71.6 (35.0–89.9)
0.2–0.5 11 88.9 (43.3–98.4) 71.1 (23.3–92.3) 71.1 (23.3–92.3)
0.5–1.0 10 77.8 (36.5–93.9) 77.8 (36.5–93.9) 77.8 (36.5–93.9)
>1.0 16 100 (−) 100 (−) 100 (−) 0.039**
RFS recurrence-free survival, CI confidence interval
*Log-rank test for equality of survivor functions, **Global log-rank test for the trend of survivor functions
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surgery.
It is interesting that re-excision appeared to be a sig-
nificant predictor of RFS when analysed as a potential
prognostic event. The reason, therefore, might lie in the
fact that re-excision led to wider negative margins. The
margin width attained surgically was a statistically sig-
nificant predictor of the outcome in the univariate and
the regression analysis in the subgroup analysis of 48Fig. 2 Effects of re-excision on recurrence-free survivalpatients with negative margins. None of the patients
with negative margins above 1 cm had a local recurrence
during follow-up. Accordingly, a surgical margin width
of 1 cm was a cutoff point in our series. However, this
was the histologically assessed margin width in the
pathologic specimen, and we cannot conclude which
safety margins planned preoperatively are needed in
order to obtain a histologically clear margin of 1 cm.
Hence, the recommended lateral safety margins ranging
from 2 to 3 cm might be justified in most of the cases
localized at the trunk or proximal extremities, whenever
feasible [7, 10, 23, 27, 28].
A high need for reconstructive procedures was observed
in our patient population (47.1%) as a consequence of wideTable 4 Results of multivariate analysis on recurrence-free
survival in the entire cohort (N = 68)
Category (reference) Hazard ratio 95% CI P
Histologic grade: G2 (vs. G1) 5.99 1.15–31.34 0.034
Tumour site: upper extremity (vs. other) 2.21 0.43–11.28 0.339
Wound closure at primary resection:
primary (vs. tissue transfer)
6.48 0.76–55.38 0.088
Re-excision: yes (vs. no) 0.23 0.06–0.93 0.039
CI confidence interval
Table 5 Results of multivariate analysis on recurrence-free
survival in the subgroup of patients with data available on




Histologic grade: G2 (vs. G1) 9.43 2.38–37.43 0.001
Tumour site: upper extremity (vs. other) 1.60 0.7–38.4 0.763
Wound closure at primary resection:
primary (vs. tissue transfer)
5.84 0.68–50.18 0.108
Closest negative margin width:
>1.0 cm (vs. ≤1.0 cm)
0.01 0.01–0.03 <0.001
CI confidence interval
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be performed in 30.2, 30.3 and 72.2% of all patients treated
in other institutions that did not use MMS [3, 5, 8]. It is
notable that the highest rate was reported by a plastic sur-
gical department, presumably due to a selection bias. This
observation might also give the impression that plastic sur-
geons are more inclined to perform reconstructive proce-
dures when they are also responsible for tumour resection.
However, these retrospective observations cannot be used
to evaluate the treatment approaches of the different disci-
plines involved. The use of reconstructive surgery in our
series displayed an improved outcome in univariate ana-
lysis, but this distribution failed to reach statistical signifi-
cance in multivariate analysis, because the use of
reconstructive surgery was associated with a larger margin
width. The median negative surgical margin width was
0.5 cm for primary closed wounds and 1.3 cm for wounds
with plastic surgical tissue transfer. The reason, therefore,
might be a selection bias where wider resections necessi-
tated the use of reconstructive surgery more frequently.
Vice versa, plastic surgical tissue transfer enabled wider re-
sections due to the safe wound coverage and, therefore,
might have led to more radical resections.
Only three patients received adjuvant radiation in our
series. Thus, we cannot make any reliable conclusions
regarding the efficacy of adjuvant radiotherapy. Never-
theless, adjuvant radiotherapy remains a treatment op-
tion for tumours that only can be resected with close or
positive surgical margins in critical anatomic sites [5, 30].
Radiation can also be used as an exclusive treatment
option in locally advanced tumours where further sur-
gery is not possible [31]. A retrospective study by the
MD Anderson Cancer Center analysed the outcome
of 53 DFSP patients treated with pre- or postopera-
tive radiation and presented a local control rate of
98% after 5 years [32]. The authors recommended ad-
juvant radiation for patients with large or recurrent
tumours or when surgical attempts at wide margins
would result in significant morbidity. Finally, the question
remains whether adjuvant radiotherapy should be appliedin patients with FS-DFSP despite negative margins. To
date, there are no studies that have analysed the prognos-
tic effects of radiation on both DFSP subtypes separately.
Hence, there are no clear suggestions whether radiation
should be applied generally in patients with R0-resected
FS-DFSP.
There are no randomized controlled studies to date
comparing MMS and WLE, but MMS seems to result in
significantly lower local recurrence rates [3, 19–22].
Mohs micrographic surgery should be preferred particu-
larly in the treatment of head and neck lesions, because
it allows greater preservation of normal tissue, resulting
in a better functional and aesthetic outcome [33]. Al-
though superior to WLE, MMS has some limitations
when large or subfascial tumours at the trunk or the dis-
tal extremities are involved [3]. However, the current
series is not able to comment on the use of MMS, be-
cause there were no patients in our database who were
treated with MMS, either in our or the referring institu-
tions. Despite consistent reports about the advantages of
MMS, it is still not a common procedure in German
clinical routine [15].
Finally, the intervals of follow-up care should be ad-
dressed so that recurrences can be detected at an early
disease stage. Unfortunately, the other centres did not
delineate their follow-up strategies. The German guide-
lines recommend clinical examinations only every
6 months during the first 5 years but state explicitly that
reliable data do not exist [34]. In the present study, the
mean time to local recurrence was 9 months in patients
in whom local recurrence occurred. However, we were
not able to assess the median time to local recurrence
because of the low number of recurrence events. The re-
cent MSKCC series with 159 patients reported a
medium time to local recurrence of 32 months [6].
Therefore, intense follow-ups during the first 5 years
seem reasonable. The last recurrence in our series oc-
curred after two and a half years. This observation raises
the question whether a follow-up up to 5 years might be
adequate for patients with DFSP or should continue
even after 5 years. In contrast to our study, the INT and
MSKCC also reported late recurrences that developed
more than 5 years after primary diagnosis. However, be-
cause of the small number of events after 5 years, we
cannot conclude whether follow-up examinations are
necessary after this long time period. The follow-up
management for DFSP in our institution includes clinical
examinations and contrast-enhanced MRIs every
3 months in the first 2 years and then every 6 months
for three more years. The decision whether follow-up
MRIs should be continued after 5 years for every 6 or
12 months is based on the previous tumour behaviour
and the decision of the informed patient. Finally, we
have to state that this follow-up strategy is only based
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tients suffering late recurrences and is not supported by
any data of high evidence.
Conclusions
In summary, this study provides long-term follow-up
data that may help clinicians estimate the prognosis of
patients with DFSP more accurately and to guide clinical
decisions after inadequate surgery and when MMS is
not available. Adverse prognostic features in our series
included the FS-DFSP subtype and close resection mar-
gins. The data from this study could underscore the
benefit of re-excision after R1 and marginal R0 resection.
Re-excision to attain wide, clear margins has been deter-
mined to be an effect method to achieve a high rate of
local control in the large subset of patients who present
after R1 or marginal R0 resection.
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